The National Health Commission (NHC) has issued a notification regarding the fifth batch of pediatric drugs encouraged for research and development. The list includes 15 varieties, encompassing systemic anti-infective drugs, respiratory system medications, anti-tumor drugs, and immune modulators. This edition features 25 specifications and 8 dosage forms, and is notable for having 8 fewer varieties compared to the recommendation version released in May of this year.
Initiated in 2016, the list has seen 30 drugs approved for marketing, including neurological, gastrointestinal and metabolic, and cardiovascular medications, with 15 of those being therapies for rare diseases. The latest update aims to further stimulate innovation and development in pediatric pharmaceuticals, ensuring a wider range of treatment options for children. – Flcube.com
